EPCAM and neoplasm: Catumaxomab antineoplastic activity has been confirmed in vitro, notably in malignant ascites, resulting in a decreased rate of EpCAM plus cells and the release of proinflammatory cytokines (interferon-γ, tumor necrosis factor-α, interleukin- (IL-) 2, and IL-6), which enables tumor cells of PM to be specifically identified by catumaxomab via the anti-EpCAM-binding site [64, 65].